Overview

Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)

Status:
Completed
Trial end date:
2010-11-10
Target enrollment:
Participant gender:
Summary
This study will examine the safety and efficacy of the addition of sitagliptin (MK-0431) compared to placebo in patients with type 2 diabetes mellitus with inadequate glycemic control who are taking pioglitazone and metformin.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Glipizide
Metformin
Pioglitazone
Sitagliptin Phosphate